Showing that a supplement changes its circulating concentration is not the same as demonstrating the intended clinical effect. CARNIDIAL tested both levels of that claim. Carnitine is not a peptide. Primary study
Trial question and result
Ninety-two people beginning hemodialysis were assigned to intravenous L-carnitine or placebo for one year in a multicenter, double-blind trial. Supplementation raised carnitine concentrations, but the study did not demonstrate improved erythropoietin responsiveness on its resistance-index endpoint. Primary report
Our appraisal: target engagement is only one step
The biochemical response establishes that the intervention affected the measured carnitine pool. It does not prove that this pool was the limiting factor governing anemia treatment response. Several physiological and care-related influences can contribute to that outcome.
The resistance index combines medication requirement, body weight, and hemoglobin. Changes in those components should be examined individually alongside the composite ratio. A similar index can sometimes arise from different component trajectories.
Patients beginning dialysis are not necessarily equivalent to long-term dialysis patients selected for persistent treatment resistance. The inclusion criteria define the population-level question. A null result in an unselected incident population should not be used to claim that every possible resistant subgroup has been definitively excluded; conversely, subgroup hypotheses do not overturn the trial's overall finding.
The direct between-group comparison is more informative than improvement within either arm. Background anemia management and adaptation after dialysis initiation can change outcomes in both groups.
Full review should inspect prespecified covariates, baseline carnitine status, iron management, missing data, and adverse events. The central result remains a dissociation between successful biochemical supplementation and an unconfirmed clinical-response benefit. It does not justify a general anemia-treatment claim based solely on raising carnitine levels.
Frequently asked questions
Is carnitine a peptide?
No.
Did supplementation raise measured carnitine?
Yes.
Did that establish improved erythropoietin responsiveness?
No.
Were participants beginning dialysis?
Yes.
Is that identical to selecting long-term resistant patients?
No.
Should the resistance-index components be inspected?
Yes.
What is the main lesson?
A biochemical change does not automatically deliver the intended clinical effect.